Revised Prices of Anti-Cancer Medicines from Nov 9
Estimated annual savings to consumers expected to be above Rs 3500 crore
UdaipurTimes, Nov 7, 2026 - National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, capped trade margins on MRP of 137 anti-cancer drugs, based on the recommendations of Expert Committee constituted by the Directorate General of Health Services (DGHS) under Ministry of Health and Family Welfare on October 17, 2026. The revised prices of these drugs will come into effect from November 9, 2026, as per an official press release.
As on date, 76 pharmaceutical companies have reported revised MRP for 1225 anti-cancer formulations, covering 121 drugs. Reduction in the MRP have been reported in 1031 formulations of anti-cancer medicines, with 600 brands reporting above 50% reduction and the highest reduction being 96.45%. Further, of the 137 identified anti-cancer drugs, there are 10-15 drugs which are yet to be launched in India. However, Trade Margin Rationalisation (TMR) will be applicable on these drugs also as and when they are launched.
As a result of the price reductions to be effected from November 9, 2026, the estimated annual savings to consumers would be Rs 3,502.31 crore.
